These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29674118)

  • 61. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
    Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
    BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
    Ni YC; Zhao JG; Zhang MN; Zhang YJ; Yang ZY; Chen N; Chen JR; Shen PF; Sun GX; Zhang XM; Li YH; Zeng H
    Asian J Androl; 2022; 24(2):154-160. PubMed ID: 34380864
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction.
    Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Topazio L; Boccasile S; Ditonno P; Chiodini P; Schips L
    Clin Genitourin Cancer; 2017 Oct; 15(5):520-525. PubMed ID: 28478884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association of Tissue Abiraterone Levels and
    Mostaghel EA; Cho E; Zhang A; Alyamani M; Kaipainen A; Green S; Marck BT; Sharifi N; Wright JL; Gulati R; True LD; Loda M; Matsumoto AM; Tamae D; Penning TN; Balk SP; Kantoff PW; Nelson PS; Taplin ME; Montgomery RB
    Clin Cancer Res; 2017 Aug; 23(16):4592-4601. PubMed ID: 28389510
    [No Abstract]   [Full Text] [Related]  

  • 68. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.
    Agarwal N; Alex AB; Farnham JM; Patel S; Gill D; Buckley TH; Stephenson RA; Cannon-Albright L
    J Urol; 2016 Oct; 196(4):1112-6. PubMed ID: 27150425
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer.
    Shiota M; Endo S; Tsukahara S; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38688318
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.
    Li T; Franco-Villalobos C; Proskorovsky I; Sorensen SV; Tran N; Sulur G; Chi KN
    Cancer; 2019 Feb; 125(4):626-632. PubMed ID: 30521063
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer.
    Yashi M; Nishihara D; Yokoyama M; Fuchizawa H; Okazaki A; Takei K; Suzuki I; Sakamoto K; Kijima T; Kobayashi M; Kamai T
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1762. PubMed ID: 36470854
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
    McKay RR; Werner L; Jacobus SJ; Jones A; Mostaghel EA; Marck BT; Choudhury AD; Pomerantz MM; Sweeney CJ; Slovin SF; Morris MJ; Kantoff PW; Taplin ME
    Cancer; 2019 Feb; 125(4):524-532. PubMed ID: 30427533
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
    Jimenez Romero ME; Gallego MC; Navarro Serrato JC; Sanchez Hurtado MA; Santotoribio JD
    Anticancer Res; 2021 Aug; 41(8):3955-3968. PubMed ID: 34281859
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
    Friedlander TW; Graff JN; Zejnullahu K; Anantharaman A; Zhang L; Paz R; Premasekharan G; Russell C; Huang Y; Kim W; Aggarwal RR; Lin AM; Fong L; Alumkal JJ; Beer TM; Sharifi N; Alyamani M; Dittamore R; Small EJ; Paris PL; Ryan CJ
    Clin Genitourin Cancer; 2017 Dec; 15(6):733-741.e1. PubMed ID: 28655452
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Zein J; Gaston B; Bazeley P; DeBoer MD; Igo RP; Bleecker ER; Meyers D; Comhair S; Marozkina NV; Cotton C; Patel M; Alyamani M; Xu W; Busse WW; Calhoun WJ; Ortega V; Hawkins GA; Castro M; Chung KF; Fahy JV; Fitzpatrick AM; Israel E; Jarjour NN; Levy B; Mauger DT; Moore WC; Noel P; Peters SP; Teague WG; Wenzel SE; Erzurum SC; Sharifi N
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2187-2193. PubMed ID: 31932420
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.
    Tsao CK; Sfakianos J; Liaw B; Gimpel-Tetra K; Kemeny M; Bulone L; Shahin M; Oh WK; Galsky MD
    Oncologist; 2016 Dec; 21(12):1414-e9. PubMed ID: 27742908
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
    Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
    Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.